Merck Animal Health, a division of Merck & Co. (MRK), on Thursday announced a definitive agreement to acquire TARGAN, a privately held developer of biodevice solutions for the poultry industry, for undisclosed consideration.
The transaction is expected to close in the third quarter of 2026.
The acquisition is expected to expand Merck Animal Health's poultry portfolio with TARGAN's biodevice technologies,
The expansion includes WingScan, an automated chick sex-sorting system that uses vision technology and proprietary algorithms to process up to 160,000 chicks per hour.
The deal also adds high-speed precision ocular spray technology for administering vaccines to day-old chicks and enhances Merck Animal Health's device development capabilities across multiple animal species.
Merck Animal Health has been an investor in TARGAN since 2017 and is one of the company's largest shareholders.
In the pre-market trading, Merck & Co. is 0.56% higher at $119.73 on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.